Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of APG-115 alone or combined with APG-2575 in relapsed/refractory T-PLL or NHL
CTR20210888Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin, lisaftoclax in T-cell prolymphocytic leukemia (T-PLL), non-Hodgkin lymphoma (NHL), sponsored by Suzhou Yasheng Pharmaceutical. Started Jul 2021; status: active.
02
Drugs
alrizomadlinlisaftoclax
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20210888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210888.